Katrin Schneider

Title: Katrin Schneider: Innovator in Pharmaceutical Compositions

Introduction

Katrin Schneider is a notable inventor based in Mannheim, Germany. She has made significant contributions to the field of pharmaceuticals, particularly in the treatment of Hepatitis C Virus (HCV). Her innovative work has led to the development of a unique solid pharmaceutical composition that showcases her expertise and dedication to advancing medical science.

Latest Patents

Katrin Schneider holds one patent titled "Solid pharmaceutical compositions for treating HCV." This invention features solid pharmaceutical compositions that comprise Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes a first layer comprising 100 mg of Compound 1, along with a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all formulated in amorphous solid dispersion. Additionally, the second layer consists of 40 mg of Compound 2, also combined with a hydrophilic polymer and surfactant, formulated in amorphous solid dispersion.

Career Highlights

Katrin Schneider is associated with AbbVie Inc., a leading global biopharmaceutical company. Her work at AbbVie has allowed her to focus on innovative solutions for complex health challenges. Her contributions to pharmaceutical research have been instrumental in developing effective treatments for HCV.

Collaborations

Katrin has collaborated with several esteemed colleagues, including Nancy E Sever and Ulrich Westedt. These collaborations have fostered a productive environment for innovation and have contributed to the success of her projects.

Conclusion

Katrin Schneider's work exemplifies the impact of innovation in the pharmaceutical industry. Her patent for solid pharmaceutical compositions represents a significant advancement in the treatment of HCV. Through her career at AbbVie and her collaborations, she continues to contribute to the field of medicine, improving the lives of many patients.